Deborah Weitzman, CEO of Cardinal Health’s Pharmaceutical and Specialty Solutions (PSS) segment, sold 6,665 shares on Aug. 18 at $235.30 per share, for a total value of about $1.57 million. The sale was disclosed as not being made under a pre-scheduled Rule 10b5-1 trading plan, which means the timing was discretionary rather than automatically set in advance. Weitzman runs a major operating segment, so her transactions can draw attention because they come from an executive with direct visibility into day-to-day business performance. That said, insider sales can happen for many non-business reasons such as taxes, diversification, or personal liquidity needs, and a single sale does not by itself indicate anything about the company’s fundamentals. The trade also occurred as part of a notable cluster of insider selling at Cardinal Health. On the same day (Aug. 18), CFO Jason Hollar sold about $5.02 million of stock, CIO Stephen Mason sold about $727,000, and Jessica Mayer sold about $915,000. Another executive, Mary Scherer, sold about $523,000 the following day. Clusters can reflect shared timing around reporting windows or compensation-related selling, but investors typically look for whether buying accompanies selling and whether sales persist over time.